ProCE Banner Activity

Extended Follow-up From the ALCANZA Phase III Trial of Brentuximab Vedotin vs Methotrexate or Bexarotene for Previously Treated CD30-Positive CTCL

Slideset Download
Conference Coverage
At a median follow-up of 33.9 months, brentuximab vedotin showed superior outcomes and durable responses vs either methotrexate or bexarotene for patients with previously treated, CD30-positive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma.

Released: December 20, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology